Finn
QURE Biotechnology · Gene therapy · Clinical stage · Rare disease · Thesis updated November 8, 2026

FDA sets May 2027 decision date as pivotal trial finalizes

01 Running thesis

One asset, two regulators, renewed hope

In late 2026, the FDA accepted uniQure's Biologics License Application for accelerated approval of AMT-130. The agency granted priority review and set a target action date of May 1, 2027. The U.K. regulator also validated a corresponding marketing application.

A massive cash balance of $768.4 million extends the runway into 2030, giving the company years of flexibility to fund its operations. The company also finalized the design for its required confirmatory trial, aiming to enroll approximately 200 patients.

The bull case is clear. The U.S. accelerated approval pathway has a concrete decision date, and the company has the cash to follow it. Furthermore, the pipeline is showing early life, with the AMT-260 epilepsy program demonstrating meaningful seizure reductions in its lowest dose cohort.

The bear case centers on the regulatory finish line. The FDA expects the required standard-of-care confirmatory trial to be well underway by the time of any accelerated approval. The agency also set a high bar by requiring Total Functional Capacity at 36 months as the confirmatory endpoint. An expected Advisory Committee meeting adds significant binary risk before the May 2027 decision.

Nov 2026▲The FDA accepted the BLA for AMT-130 under accelerated approval, granting priority review and a May 1, 2027 decision date. The company also finalized the design of its required confirmatory trial.
Jul 2026→The FDA required Total Functional Capacity at 36 months for the AMT-130 confirmatory study. The company also stated it expects an Advisory Committee meeting, adding binary risk.
Jul 2026▲The FDA reversed its prior stance, agreeing an accelerated approval submission for AMT-130 is reasonable based on existing data. Q2 ending cash hit $810.3 million, extending the runway to 2030.
May 2026▲uniQure added a major new catalyst by planning a U.K. AMT-130 filing in Q3 2026 after MHRA feedback. It also extended cash runway guidance into the second half of 2029.
May 2026▼The company formally discontinued AMT-162 for ALS. That narrows the pipeline and makes AMT-130 even more important.
Mar 2026▼The FDA's position on AMT-130 became clear. It does not view the Phase I/II data with an external control as enough main proof for a U.S. marketing application and strongly recommended a new sham-controlled study.
Mar 2026→Management planned a Q2 2026 Type B meeting with the FDA to discuss the U.S. pivotal trial design. This gave investors a next step, but not yet a cost or timeline.
Nov 2025▼The earlier plan for a near-term U.S. BLA filing broke after the FDA no longer appeared to support the external control pathway. Positive 3-year data could not remove the regulatory overhang.
02 Business model

Royalties fund a trial story

uniQure develops one-time gene therapies for serious rare diseases. These treatments try to fix or change disease biology with a single administration, rather than requiring chronic dosing.

The only approved product tied to uniQure is HEMGENIX for Hemophilia B. CSL Behring commercializes it, and uniQure receives royalties and milestone payments. License revenue makes up the vast majority of the revenue base today.

The company previously subcontracted its manufacturing of HEMGENIX to Genezen. In April 2026, uniQure agreed to terminate this commercial supply agreement, ending its supply obligation once specified batches are delivered. The company relies on outsourced manufacturing for its clinical-stage pipeline.

The core value driver is the clinical and regulatory success of its pipeline. The business relies on a massive cash reserve to fund costly trials until its candidates can be commercialized or licensed.

03 Product portfolio

What uniQure is betting on

Growth engine

AMT-130

The lead program for Huntington's disease. The FDA accepted its BLA for priority review with a May 1, 2027 target action date.

Cash cow

HEMGENIX

An approved gene therapy for Hemophilia B sold by CSL Behring. It provides royalty revenue but is not the primary driver of the stock.

Option

AMT-260

A clinical candidate for refractory mesial temporal lobe epilepsy. Early data showed meaningful seizure reductions for a subset of low-dose patients.

Option

AMT-191

A clinical candidate for Fabry disease. Dosing in mid- and high-dose cohorts remains paused pending evaluation of dose-limiting toxicities.

04 Business segments

Revenue is one stream today

License revenues100%flat
Contract manufacturing revenues0%declining
Collaboration revenues0%flat

For Q3 2026, uniQure reported revenue primarily from licenses. The company operates as a single business segment focused on gene therapy development.

05 Risk factors

What could break the story

Confirmatory trial requirements

High impact · High odds

The FDA accepted the BLA submission, but it requires a 200-patient standard-of-care confirmatory trial to be well underway before potential approval. The FDA wants Total Functional Capacity at 36 months as the primary endpoint, which is a very high bar.

We watchFDA alignment on the confirmatory study enrollment rates for AMT-130.

Advisory Committee risk

High impact · Medium odds

Management expects an FDA Advisory Committee meeting for the AMT-130 application. This public review introduces severe binary risk, as the panel will heavily scrutinize the intermediate endpoints and safety profile.

We watchScheduling of an AdCom and the release of agency briefing documents.

Pipeline safety setbacks

Medium impact · Medium odds

Dosing in the AMT-191 trial for Fabry disease is paused due to dose-limiting toxicities. Early-stage development risk remains high across the broader portfolio.

We watchUpdates on the AMT-191 clinical hold and whether dosing resumes.

BLA review timelines

High impact · Medium odds

The FDA accepted the BLA with a May 2027 action date, but could still issue a complete response letter. A rejection would severely damage the stock.

We watchFDA and MHRA decisions on the applications around their target action dates.
06 Quick answers

In one breath

What is the status of AMT-130?

The FDA accepted a U.S. Biologics License Application for accelerated approval, setting a target decision date of May 1, 2027. The company also has an application under review in the U.K.

How is uniQure funded?

The company reported $768.4 million in cash and investments at the end of Q3 2026, extending its runway into 2030. The company also earns royalties on HEMGENIX.

What happened to the manufacturing business?

uniQure terminated its commercial supply agreement with Genezen in April 2026. It is moving away from supplying HEMGENIX after final batches are delivered.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. uniQure Q3 2026 Earnings Transcript
  2. uniQure Q2 2026 Form 10-Q
  3. uniQure Q2 2026 Earnings Transcript
08 Explore the industry

Comparable Biotechnology companies

Companies near uniQure N.V. in Finn's Biotechnology industry ranking.

Get started with Finn today